Skip to content
Clinical Trials – home

Peyronie's disease Life with Disease

2 / 2 trials open to patients2 countries

In short

Peyronie's disease is a condition where scar tissue forms beneath the skin of the penis, causing it to curve or bend during erections, sometimes accompanied by pain. Understanding how this condition progresses, what complications might arise, and how it affects everyday life can help those diagnosed and their families navigate the journey ahead with greater confidence and preparedness.

Key points

  • Peyronie's disease has two phases—an acute phase lasting 6-18 months where scar tissue actively forms and pain is common, followed by a chronic phase where the curvature stabilizes and pain usually decreases
  • Early treatment during the acute phase may prevent the condition from worsening and can lead to better outcomes than waiting until the chronic phase
  • The condition rarely resolves on its own—most cases remain stable or progress without treatment, making medical consultation important
  • Peyronie's disease can be painful and may cause erectile dysfunction, but it is not life-threatening and is not caused by cancer
  • A bend greater than 30 degrees can make sexual intercourse painful or impossible for both the person with the condition and their partner
  • The condition affects not just physical function but also emotional wellbeing, self-esteem, and intimate relationships, making psychological support important
  • Multiple treatment options exist, including oral medications, injections, stretching devices, and surgery for severe cases
  • Family support plays a crucial role in helping patients navigate treatment options, including participation in clinical trials that may offer access to new therapies

Understanding the Prognosis

When someone receives a diagnosis of Peyronie's disease, one of the first questions that comes to mind is what to expect in the long term. The good news is that this is not a life-threatening condition, and it is not caused by cancer. However, the outlook varies from person to person, and understanding what might happen can help reduce anxiety and guide treatment decisions.

Peyronie's disease rarely goes away on its own. In most people with the condition, it will either remain stable or may become slightly worse during the initial stages. Medical experts estimate that about 6% to 10% of people between the ages of 40 and 70 with penises have Peyronie's disease, though the actual number might be higher since many people feel too embarrassed to seek help.

The disease has two distinct phases. The acute phase lasts between six and 12 months, sometimes extending up to 18 months. During this time, the scar tissue forms and the curvature may change, either improving or worsening. Pain during erections is common in this stage. After this, the condition enters the chronic or stable phase, where the curvature no longer progresses. Pain usually decreases during the chronic phase, though it can sometimes persist. Some men develop erectile dysfunction during the chronic phase, which can further affect sexual function.

Early treatment during the acute phase may work better than waiting until the chronic phase sets in. Even for those who have had Peyronie's disease for some time, treatment may help ease symptoms such as pain, curving, and shortening of the penis. Most men with Peyronie's disease are able to remain sexually active, especially with appropriate treatment and support.

Natural Progression Without Treatment

Understanding how Peyronie's disease develops when left untreated helps patients make informed decisions about whether to pursue treatment. The condition is a disorder of wound healing involving the tunica albuginea, the elastic sheath that surrounds the erectile tissue of the penis. When trauma or repeated minor injuries occur to this tissue, the healing process can go awry, leading to the formation of fibrous scar tissue, also called plaque. This is different from the plaque that builds up in blood vessels or on teeth—it refers to hardened areas of scar tissue.

The leading theory about what causes Peyronie's disease relates to trauma or injury to the penis during sexual activity. This might happen during vigorous intercourse, or even if a man rolls over during a nighttime erection. Research has found that men who engage in more vigorous or frequent intercourse appear more likely to develop the condition. The inflammation from trauma is thought to trigger abnormal scar tissue formation. Over time, this plaque builds up and prevents the penis from expanding normally during an erection, causing it to curve upward, downward, or to one side, depending on where the scar tissue is located.

If left untreated, the acute phase unfolds over months. During this period, the scar tissue is actively forming, and the curvature may become more pronounced. Pain during erections is often present. After this active phase, the disease enters a passive or chronic phase where the plaque has set and the curvature no longer worsens. The pain typically subsides by this time, although it can occasionally persist. The penis may have shortened compared to before the condition developed, and erectile dysfunction may emerge during this phase.

While some cases of Peyronie's disease resolve on their own without treatment, this is unusual. Most often, the condition remains stable or progresses. Without intervention, men may experience ongoing difficulties with sexual function, including painful intercourse, inability to achieve penetration, or psychological distress related to the appearance and function of the penis.

Possible Complications

Peyronie's disease can lead to several complications that affect both physical function and emotional wellbeing. Understanding these potential complications can help patients recognize problems early and seek appropriate care.

One of the most serious complications is corporal rupture, also known as penile fracture. This occurs when the tubes inside the penis called the corpora cavernosa actually break during an erection. This is a rare but serious injury that can happen after certain treatments or during sexual activity in men with severe disease. A corporal rupture requires surgical repair, and damage to the penis might not fully heal even after surgery. Blood vessels in the penis may also break, causing blood to collect under the skin in what is called a hematoma. Large hematomas may require a procedure to drain the blood, and in some cases, skin and soft tissue death may develop in that area, potentially requiring surgery.

Erectile dysfunction is a common complication of Peyronie's disease. It may develop during the chronic phase and can result from several factors: the scar tissue itself may interfere with blood flow to the penis, the curvature may make achieving a firm erection more difficult, or the psychological stress of the condition may contribute. If the bend in the penis is greater than 30 degrees—which looks similar to the hands of a clock at 1:00—it can make sex painful or impossible for both the person with the condition and their partner.

Shortening of the penis is another complication that affects nearly all men with Peyronie's disease to some degree. The scar tissue forces the penis to contract on the affected side, resulting in a loss of length. Some men also experience a loss of girth, with the shaft appearing narrower or taking on an hourglass shape where the scar tissue encircles the penis. This physical change can be distressing and may affect self-esteem and sexual confidence.

Pain during sexual activity, known as dyspareunia, is a complication that affects both the person with Peyronie's disease and their partner. The curvature and rigidity of the scar tissue can make penetration uncomfortable or impossible. Even when intercourse is possible, the altered shape of the penis may cause discomfort for both parties. This can lead to avoidance of intimacy and strain on relationships.

Impact on Daily Life

Peyronie's disease affects more than just physical function—it touches nearly every aspect of daily life, from intimate relationships to emotional health and self-confidence. Understanding these impacts can help patients and their families prepare for the challenges ahead and find effective coping strategies.

The physical changes caused by Peyronie's disease can significantly affect sexual activity. When the penis curves sharply, becomes painful during erections, or loses rigidity due to concurrent erectile dysfunction, sexual intercourse may become difficult or impossible. Many men report anxiety during intimacy or choose to avoid intimacy completely. This avoidance is often driven by fear of pain, embarrassment about the appearance of the penis, or worry about being unable to satisfy a partner. The progressive development of noticeable curvature, pain, or inability to have intercourse often prompts men to finally seek medical help, sometimes with encouragement from their spouse or partner.

Emotional and psychological impacts are profound. Peyronie's disease can cause significant distress due to the deformity and impaired appearance and function of the penis. Many men experience depression or low self-esteem as a result of the condition. Feelings of anxiety, frustration, and isolation are common, particularly when men feel too self-conscious to discuss their symptoms with healthcare providers or partners. The condition can affect how men feel about themselves and their masculinity, leading to a loss of sexual confidence.

Relationship challenges often arise when Peyronie's disease is present. The physical limitations may prevent normal sexual activity, leading to frustration and misunderstanding between partners. Communication difficulties are common—many men feel embarrassed discussing the condition, which can leave partners confused or worried. This breakdown in communication can create distance in relationships and leave both individuals feeling isolated. Partners may not understand what is happening or may mistakenly believe the problem is related to attraction or relationship issues rather than a medical condition.

Work and social activities are generally not directly affected by Peyronie's disease, as the condition does not cause problems with urination or physical mobility. However, the emotional toll—including anxiety, depression, or preoccupation with symptoms—may indirectly affect concentration, productivity, or willingness to engage in social situations.

Coping strategies can help manage the impact of Peyronie's disease on daily life. Counseling can help couples maintain an active sexual life and address relationship strain. Working with a therapist or counselor who specializes in sexual health can help address concerns about self-esteem and sexual function, improving overall wellbeing. Open communication with a partner about symptoms, fears, and needs is essential. Many couples find that exploring alternative forms of intimacy while undergoing treatment helps maintain closeness. Joining support groups or connecting with others who have Peyronie's disease can reduce feelings of isolation and provide practical advice.

Support for Family and Clinical Trial Participation

Family members and partners play a crucial role in supporting someone with Peyronie's disease, especially when considering participation in clinical trials. Understanding what clinical trials are, why they matter, and how to support a loved one through the process can make a significant difference.

Clinical trials are research studies that test new treatments, devices, or approaches to managing Peyronie's disease. They are essential for advancing medical knowledge and finding better ways to treat the condition. Because the clinical landscape of Peyronie's disease is constantly changing, with growing interest in non-invasive therapeutic options, clinical trials offer patients access to cutting-edge treatments that might not yet be widely available. Participating in a trial can provide hope when standard treatments have not been successful.

Families can support their loved ones in finding and preparing for clinical trial participation in several ways. First, help gather information about available trials. This might involve searching online databases, asking healthcare providers about ongoing studies, or contacting academic medical centers that specialize in men's health or urology. Many medical centers maintain lists of clinical trials for various conditions, including Peyronie's disease.

Understanding eligibility requirements is important. Clinical trials often have specific criteria about who can participate, such as age ranges, severity of curvature, how long the person has had symptoms, or whether they have tried other treatments. Family members can help review these requirements and organize medical records that might be needed during the screening process.

Emotional support is invaluable throughout the trial process. Participating in a clinical trial can bring hope but also uncertainty, as some participants may receive a placebo or experimental treatment rather than standard care. Family members should be prepared to listen without judgment, acknowledge fears and concerns, and provide encouragement. Remember that the decision to participate should ultimately be the patient's choice, made after fully understanding the potential benefits and risks.

Practical assistance matters too. Clinical trials often require multiple visits to research centers, which may be far from home. Families can help with transportation, attend appointments if the patient wishes, take notes during visits with research coordinators, and help track symptoms or side effects that need to be reported to the study team.

Partners should also understand that some clinical trials may place restrictions on sexual activity during certain phases of treatment to ensure patient safety and study accuracy. Planning together for these periods and discussing alternative forms of intimacy can help maintain relationship closeness.

Education is empowering for both patients and families. Taking time to learn about Peyronie's disease—its causes, progression, and treatment options—helps families provide informed support and ask meaningful questions during medical appointments. It also reduces the sense of mystery and anxiety that often surrounds the condition. Many healthcare providers welcome the presence of supportive family members at appointments and appreciate their involvement in treatment decisions.

Finally, families should encourage their loved ones not to feel embarrassed about seeking help. Peyronie's disease is a common medical condition that healthcare providers encounter regularly. The more open families can be in discussing the condition and exploring all treatment options, including clinical trials, the better the outcomes are likely to be.

Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Collagenase clostridium histolyticum (Xiaflex) – An FDA-approved injectable medication that breaks down collagen in scar tissue to help reduce penile curvature in men with Peyronie's disease who have a palpable plaque and a curve greater than 30 degrees
  • Verapamil – A medication that can be injected into the scar tissue or applied topically to help reduce scarring and plaque formation
  • Interferon – An injectable medication given directly into the scar tissue to help reduce scarring
  • Pentoxifylline – An oral medication that may improve blood flow to the penis and help reduce scarring
  • Colchicine – An oral medication sometimes used in combination with vitamin E to reduce scarring
  • Carnitine – An oral medication that may help reduce scarring
  • Corticosteroids – Injectable medications that can reduce inflammation and pain
  • NSAIDs (such as ibuprofen or naproxen) – Over-the-counter oral medications used to treat pain associated with Peyronie's disease
  • Phosphodiesterase type 5 (PDE5) inhibitors (such as sildenafil/Viagra, tadalafil/Cialis, vardenafil/Levitra) – Medications used to treat erectile dysfunction that may occur with Peyronie's disease

Did you know?

  1. Peyronie's disease was first described over 450 years ago, in 1561, though it wasn't formally named until French surgeon François Gigot de la Peyronie documented it in 1743 while serving as personal physician to King Louis XV.
  2. Men with Peyronie's disease may also develop thicker, less flexible skin in other parts of their body, such as their hands and feet, including conditions like Dupuytren's contracture in the hands or plantar fasciitis in the feet.
  3. The condition may be more widespread than statistics suggest because many men feel too embarrassed to discuss it with healthcare providers, meaning the true prevalence could be significantly higher than the reported 6-10%.

Questions people often ask

This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.

Clinical trials for Peyronie's disease

Recruiting trials first

See all 2 trials →
Quick filters

2 clinical trials in this condition

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ALPROSTADIL
  • Sponsor:Fidia Farmaceutici S.p.A.
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Universitair Medisch Centrum Groningen
See all 2 trials →filters applied: condition = Peyronie's disease
Back to all diseases
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).